Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 12 of 12 matching drugs for ABCA3 — including drugs targeting any of its 163 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
bosutinib CAMK2G SSL via CAMK2G 1
disulfiram, copper, alkylating agents GAPDH SSL via GAPDH 1
disulfiram, copper, alkylating agents SRSF1 SSL via SRSF1 1
motixafortide, cemiplimab, gemcitabine, nab paclitaxel CXCR4 SSL via CXCR4 1
pantoprazole, omeprazole DDAH1 SSL via DDAH1 1
plerixafor CXCR4 SSL via CXCR4 yes 1
plerixafor, temozolomide, whole-brain radiotherapy (wbrt), radiation therapy CXCR4 SSL via CXCR4 1
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study CXCR4 SSL via CXCR4 1
fingolimod S1PR2 SSL via S1PR2 yes 0
fingolimod hydrochloride S1PR2 SSL via S1PR2 yes 0
pentoxifylline PDE6H SSL via PDE6H yes 0
phenindione GGCX SSL via GGCX yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.